Progyny Inc. (PGNY)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Progyny, Inc. (PGNY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Progyny, Inc. (PGNY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Progyny Q1 Earnings Call Highlights
Progyny NASDAQ: PGNY reported what management called a strong start to 2026, with first-quarter revenue reaching a record level and profitability exceeding expectations amid continued investments in its platform and member experience.
Progyny, Inc. (PGNY) Q1 2026 Earnings Call Transcript
Progyny, Inc. (PGNY) Q1 2026 Earnings Call Transcript
Progyny (PGNY) Q1 Earnings and Revenues Beat Estimates
Progyny (PGNY) came out with quarterly earnings of $0.5 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.48 per share a year ago.
Should Value Investors Buy Progyny (PGNY) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Progyny (PGNY) Upgraded to Buy: Here's Why
Progyny (PGNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
PGNY or ALHC: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical Services stocks have likely encountered both Progyny (PGNY) and Alignment Healthcare (ALHC). But which of these two stocks is more attractive to value investors?
Progyny, Inc. (PGNY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Progyny, Inc. (PGNY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Progyny: Transitional Headwinds Hide An Undervalued Platform
Progyny (PGNY) is undervalued at 9.3x forward P/E, with strong cash flow, expanding margins, and a resilient business model post-Amazon client loss. Headline FY26 growth appears muted (5.1%–9%) due to tough comps, but underlying growth excluding Amazon is 9.3–13.3%, with stable utilization rates near 1% and covered lives still expanding. PGNY's differentiated, outcome-focused platform, high retention, and buybacks (~15% share reduction in two years) support a robust medium-term investment case.
Progyny, Inc. (PGNY) Q4 2025 Earnings Call Transcript
Progyny, Inc. (PGNY) Q4 2025 Earnings Call Transcript
Progyny (PGNY) Q4 Earnings and Revenues Surpass Estimates
Progyny (PGNY) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of $0.38 per share. This compares to earnings of $0.42 per share a year ago.
Compared to Estimates, Progyny (PGNY) Q4 Earnings: A Look at Key Metrics
The headline numbers for Progyny (PGNY) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
